Biomarkers in GIST: Partly ready for prime-time use

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Gastrointestinal stromal tumors, or GISTs, are now among the most treatable of solid malignancies. Assessing actual tumor response remains challenging; however, in this issue of Clinical Cancer Research, two articles discuss biomarkers potentially helpful in predicting response or other long-term benefits with standard tyrosine kinase therapy use.

Original languageEnglish (US)
Pages (from-to)5603-5605
Number of pages3
JournalClinical Cancer Research
Volume15
Issue number18
DOIs
StatePublished - Sep 15 2009
Externally publishedYes

Fingerprint

Biomarkers
Neoplasms
Gastrointestinal Stromal Tumors
Protein-Tyrosine Kinases
Research
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Biomarkers in GIST : Partly ready for prime-time use. / Blanke, Charles.

In: Clinical Cancer Research, Vol. 15, No. 18, 15.09.2009, p. 5603-5605.

Research output: Contribution to journalArticle

@article{ceb2795b251f41c4958396d0eec5a099,
title = "Biomarkers in GIST: Partly ready for prime-time use",
abstract = "Gastrointestinal stromal tumors, or GISTs, are now among the most treatable of solid malignancies. Assessing actual tumor response remains challenging; however, in this issue of Clinical Cancer Research, two articles discuss biomarkers potentially helpful in predicting response or other long-term benefits with standard tyrosine kinase therapy use.",
author = "Charles Blanke",
year = "2009",
month = "9",
day = "15",
doi = "10.1158/1078-0432.CCR-09-1563",
language = "English (US)",
volume = "15",
pages = "5603--5605",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - Biomarkers in GIST

T2 - Partly ready for prime-time use

AU - Blanke, Charles

PY - 2009/9/15

Y1 - 2009/9/15

N2 - Gastrointestinal stromal tumors, or GISTs, are now among the most treatable of solid malignancies. Assessing actual tumor response remains challenging; however, in this issue of Clinical Cancer Research, two articles discuss biomarkers potentially helpful in predicting response or other long-term benefits with standard tyrosine kinase therapy use.

AB - Gastrointestinal stromal tumors, or GISTs, are now among the most treatable of solid malignancies. Assessing actual tumor response remains challenging; however, in this issue of Clinical Cancer Research, two articles discuss biomarkers potentially helpful in predicting response or other long-term benefits with standard tyrosine kinase therapy use.

UR - http://www.scopus.com/inward/record.url?scp=70349463111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349463111&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-09-1563

DO - 10.1158/1078-0432.CCR-09-1563

M3 - Article

C2 - 19737947

AN - SCOPUS:70349463111

VL - 15

SP - 5603

EP - 5605

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 18

ER -